Although lncRNAs and miRNAs have been identified to affect AML therapy resistance, the specific function of lncRNA-FTX that modulates MDR of AML by directly targeting miR-342 to regulate ALG3 is not well understood. The gene discussed is ALG3; the disease is acute myeloid leukemia.